Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 March 2018Website:
http://www.gtbiopharma.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:53:59 GMTDividend
Analysts recommendations
Institutional Ownership
GTBP Latest News
SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.
GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing.
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
What type of business is GT Biopharma?
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
What sector is GT Biopharma in?
GT Biopharma is in the Healthcare sector
What industry is GT Biopharma in?
GT Biopharma is in the Biotechnology industry
What country is GT Biopharma from?
GT Biopharma is headquartered in United States
When did GT Biopharma go public?
GT Biopharma initial public offering (IPO) was on 27 March 2018
What is GT Biopharma website?
https://www.gtbiopharma.com
Is GT Biopharma in the S&P 500?
No, GT Biopharma is not included in the S&P 500 index
Is GT Biopharma in the NASDAQ 100?
No, GT Biopharma is not included in the NASDAQ 100 index
Is GT Biopharma in the Dow Jones?
No, GT Biopharma is not included in the Dow Jones index
When does GT Biopharma report earnings?
The next expected earnings date for GT Biopharma is 07 August 2024